Around 20 to 30% of women with breast cancer diagnoses have overexpressed Human epidermal growth factor receptor 2 (ERBB2, formerly HER2), which is associated with more aggressiveness and worse prognosis (6). This evidence concerns the gene ERBB2 and breast carcinoma.